Inductos (dibotermin alfa) is a protein pharmaceutical. Dibotermin alfa was first approved as Inductos on 2002-09-09. It has been approved in Europe to treat internal fracture fixation, spinal fusion, and tibial fractures.
|Common Name||Dibotermin alfa|
|Indication||internal fracture fixation, spinal fusion, tibial fractures|
|Drug Class||Growth factors: bone morphogenetic proteins|growth factors: transforming growth factors|